RU2020111305A - Предупреждение и/или лечение нейродегенеративного заболевания - Google Patents

Предупреждение и/или лечение нейродегенеративного заболевания Download PDF

Info

Publication number
RU2020111305A
RU2020111305A RU2020111305A RU2020111305A RU2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A
Authority
RU
Russia
Prior art keywords
composition
zeaxanthin
composition according
omega
fatty acid
Prior art date
Application number
RU2020111305A
Other languages
English (en)
Russian (ru)
Inventor
Алан Норман ГОВАРД
Джон НОЛАН
Риона МАЛКЭХИ
Original Assignee
Говард Фаундейшн Холдингс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Говард Фаундейшн Холдингс Лтд filed Critical Говард Фаундейшн Холдингс Лтд
Publication of RU2020111305A publication Critical patent/RU2020111305A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2020111305A 2017-12-04 2018-05-10 Предупреждение и/или лечение нейродегенеративного заболевания RU2020111305A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1720119.5 2017-12-04
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
RU2020111305A true RU2020111305A (ru) 2022-01-10

Family

ID=60950313

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020111305A RU2020111305A (ru) 2017-12-04 2018-05-10 Предупреждение и/или лечение нейродегенеративного заболевания

Country Status (15)

Country Link
US (1) US10835509B2 (enExample)
EP (2) EP3644979B1 (enExample)
JP (1) JP2021505527A (enExample)
KR (1) KR20200095452A (enExample)
AU (1) AU2018379644B2 (enExample)
BR (1) BR112020005132A2 (enExample)
CA (1) CA3071786C (enExample)
ES (1) ES3047101T3 (enExample)
GB (2) GB201720119D0 (enExample)
IE (1) IE87241B1 (enExample)
MX (1) MX2020002458A (enExample)
RU (1) RU2020111305A (enExample)
SG (1) SG11202000786RA (enExample)
WO (1) WO2019110951A1 (enExample)
ZA (1) ZA202000558B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
WO2022244727A1 (ja) * 2021-05-17 2022-11-24 小野薬品工業株式会社 認知機能を改善するための組成物
JPWO2024143060A1 (enExample) * 2022-12-26 2024-07-04

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
CA2708258C (en) * 2007-12-17 2017-05-09 Newtricious B.V. Method of producing egg yolk based functional food product and products obtainable thereby
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
TR201809213T4 (tr) * 2011-07-07 2018-07-23 Howard Foundation Holdings Ltd Kamaşma yetersizliğinin iyileştirilmesine yönelik yöntem.
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
CA2907886A1 (en) * 2013-03-28 2014-10-02 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
JP6178761B2 (ja) * 2013-07-10 2017-08-09 ライオン株式会社 内服剤
CN109068714A (zh) * 2016-02-22 2018-12-21 新粹尔私人有限公司 用于预防或治疗神经退行性疾病的组合物

Also Published As

Publication number Publication date
GB201807590D0 (en) 2018-06-27
EP4599891A2 (en) 2025-08-13
CA3071786A1 (en) 2019-06-13
EP3644979A1 (en) 2020-05-06
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
US20190167624A1 (en) 2019-06-06
JP2021505527A (ja) 2021-02-18
NZ761512A (en) 2024-01-26
US10835509B2 (en) 2020-11-17
SG11202000786RA (en) 2020-06-29
ES3047101T3 (en) 2025-12-03
ZA202000558B (en) 2021-10-27
WO2019110951A1 (en) 2019-06-13
AU2018379644A1 (en) 2020-03-19
BR112020005132A2 (pt) 2020-09-15
KR20200095452A (ko) 2020-08-10
IE87241B1 (en) 2021-07-07
GB2568986B (en) 2019-12-18
GB201720119D0 (en) 2018-01-17
MX2020002458A (es) 2020-07-20
EP3644979B1 (en) 2025-08-06
CA3071786C (en) 2023-11-14
AU2018379644B2 (en) 2024-02-08
EP4599891A3 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
RU2020111305A (ru) Предупреждение и/или лечение нейродегенеративного заболевания
ES2564025T3 (es) Composiciones que comprenden 15-HEPE y métodos de uso de las mismas
Freeman Omega-3 fatty acids in major depressive disorder.
US20130108706A1 (en) Dietary formulations
JP2021505527A5 (enExample)
CA2705936C (en) Use of omega-3-fatty acids for pain relief
JP2016053065A5 (enExample)
JP2018517787A5 (enExample)
CA3129008A1 (en) Compositions comprising 15-hepe and methods of using the same
JP2017526623A (ja) 活性物質のミネラル・アミノ酸錯体
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
RS51195B (sr) Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
US20160296487A1 (en) Lipid composition for the prevention or treatment of skin problems
KR100858988B1 (ko) 치료제
ES2332102T3 (es) Composicion que contiene acidos grasos omega 3 y acidos grasos omega 6.
JP2023030130A5 (enExample)
JP7201646B2 (ja) 経口組成物
NZ761512B2 (en) Prevention and/or treatment of neurodegenerative disease
CN108882722A (zh) 食用油中的按时释放维生素和矿物质
US12053437B2 (en) Eye health supplement
US20230263736A1 (en) Soft gelatin capsules
ES2255653T3 (es) Capsula de gelatina con vitaminas liposolubles y acidos grasos.
RU2006120614A (ru) Комбинированный продукт из питательных микроэлементов для дополнительной сбалансированной диеты при возрастных дегенеративных изменениях в области желтого пятна
CN109789178B (zh) 影响心血管效率的营养补充剂
Crawford Another Supplement for CAD Prevention Fails